Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SK-1887
- Development stage
- Unknown
- Lead developer
- Sanwa Kagaku Kenkyusho
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SK-1887 is an investigational small molecule drug candidate developed by the Japanese pharmaceutical company Sanwa Kagaku Kenkyuso. It is currently in Phase 1 clinical development for the treatment of neurological diseases. While the specific molecular target and mechanism of action have not been publicly disclosed by the developer, clinical trial records indicate that the compound is administered orally in a tablet formulation. The drug is being advanced as part of Sanwa Kagaku Kenkyuso's internal research and development pipeline, with early-stage trials focused on evaluating its safety, tolerability, and pharmacokinetic profile in human subjects.
Beyond the preview
Go deeper on SK-1887.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SK-1887.